PSTV Plus Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PSTV

Price (delayed)

$1.8

Market cap

$7.7M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.24

Enterprise value

$3.32M

Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform ...

Highlights
The EPS has surged by 63% year-on-year and by 30% since the previous quarter
Plus Therapeutics's net income has increased by 34% YoY and by 12% QoQ
The equity has dropped by 151% since the previous quarter and by 121% year-on-year
The quick ratio has contracted by 48% YoY and by 24% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.plustherapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of PSTV
Market
Shares outstanding
4.28M
Market cap
$7.7M
Enterprise value
$3.32M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.68
Earnings
Revenue
$4.91M
EBIT
-$12.92M
EBITDA
-$12.18M
Free cash flow
-$13.01M
Per share
EPS
-$4.24
Free cash flow per share
-$4.14
Book value per share
-$0.3
Revenue per share
$1.56
TBVPS
$3.49
Balance sheet
Total assets
$11.39M
Total liabilities
$12.74M
Debt
$4.18M
Equity
-$1.35M
Working capital
-$893,000
Liquidity
Debt to equity
-3.1
Current ratio
0.92
Quick ratio
0.8
Net debt/EBITDA
0.36
Margins
EBITDA margin
-247.8%
Gross margin
100%
Net margin
-271%
Operating margin
-271.1%
Efficiency
Return on assets
-97.7%
Return on equity
-805.6%
Return on invested capital
N/A
Return on capital employed
-1,954.8%
Return on sales
-263%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PSTV stock price

How has the Plus Therapeutics stock price performed over time
Intraday
-2.17%
1 week
6.51%
1 month
-4.26%
1 year
-52%
YTD
2.85%
QTD
-0.28%

Financial performance

How have Plus Therapeutics's revenue and profit performed over time
Revenue
$4.91M
Gross profit
$4.91M
Operating income
-$13.32M
Net income
-$13.32M
Gross margin
100%
Net margin
-271%
PSTV's net margin has surged by 97% year-on-year and by 33% since the previous quarter
PSTV's operating margin has surged by 97% year-on-year and by 32% since the previous quarter
Plus Therapeutics's net income has increased by 34% YoY and by 12% QoQ
The operating income is up by 32% YoY and by 11% from the previous quarter

Growth

What is Plus Therapeutics's growth rate over time

Valuation

What is Plus Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.68
The EPS has surged by 63% year-on-year and by 30% since the previous quarter
The equity has dropped by 151% since the previous quarter and by 121% year-on-year
The P/S is 74% below the last 4 quarters average of 4.5
PSTV's revenue is up by 31% QoQ

Efficiency

How efficient is Plus Therapeutics business performance
The return on sales has surged by 97% year-on-year and by 33% since the previous quarter
The ROE has shrunk by 91% QoQ
The ROA has contracted by 12% YoY and by 8% from the previous quarter

Dividends

What is PSTV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PSTV.

Financial health

How did Plus Therapeutics financials performed over time
Plus Therapeutics's total assets is 11% lower than its total liabilities
Plus Therapeutics's total assets has shrunk by 52% YoY and by 14% QoQ
Plus Therapeutics's current ratio has plunged by 50% YoY and by 16% from the previous quarter
The equity has dropped by 151% since the previous quarter and by 121% year-on-year
PSTV's debt is down by 26% year-on-year and by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.